Nuvig Therapeutics Inc.

Autoimmune Neurology

Nuvig Therapeutics Inc. is engaged in clinical research for chronic inflammatory demyelinating polyneuropathy, with interest in immune-mediated disorders that affect peripheral nerve function and motor-sensory control.

  • CIDP
  • Peripheral neuropathy
  • Immune-mediated demyelination

The sponsor’s work in this area centers on therapeutic development for neuromuscular disability associated with inflammatory nerve injury.

Hematologic Immunology

The company also funds clinical research in immune thrombocytopenia, focusing on immune-driven platelet disorders and related bleeding risk.

  • ITP
  • Thrombocytopenia
  • Autoimmune hematologic disease

This area reflects interest in immune regulation within disorders of platelet destruction and impaired hemostasis.

Inflammatory and Immune Modulation

Across its clinical program, the sponsor is focused on immune system modulation in conditions where aberrant inflammatory activity contributes to tissue dysfunction.

  • Inflammation
  • Autoimmunity
  • Immunologic therapeutics

Its research activity highlights therapeutic interest in disease areas driven by dysregulated immune responses.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study of NVG-2089 given by intravenous infusion in patients with immune thrombocytopenia to evaluate safety and effectiveness

    Recruiting

    1 1 1
    Greece Poland Spain
  • Study on the Safety and Effects of NVG-2089 for Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

    Not recruiting

    1 1
    Belgium Bulgaria France Italy Poland Spain